Novavax (NVAX) Competitors

$9.21 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$9.20 -0.01 (-0.05%)

As of 05/22/2026 07:58 PM Eastern

NVAX vs. MRNA, OCGN, AZN, JNJ, and PFE

Should you buy Novavax stock or one of its competitors? MarketBeat compares Novavax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novavax include Moderna (MRNA), Ocugen (OCGN), Astrazeneca (AZN), Johnson & Johnson (JNJ), and Pfizer (PFE).

How does Novavax compare to Moderna?

Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

In the previous week, Moderna had 9 more articles in the media than Novavax. MarketBeat recorded 16 mentions for Moderna and 7 mentions for Novavax. Novavax's average media sentiment score of 0.03 beat Moderna's score of -0.20 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	6 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

75.3% of Moderna shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novavax has lower revenue, but higher earnings than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.57	-$2.82B	-$8.15	N/A
Novavax	$1.12B	1.35	$440.30M	-$0.58	N/A

Moderna presently has a consensus target price of $35.73, suggesting a potential downside of 23.78%. Novavax has a consensus target price of $12.13, suggesting a potential upside of 31.65%. Given Novavax's stronger consensus rating and higher probable upside, analysts clearly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Novavax	-14.73%	-14.82%	1.23%

Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Novavax has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market.

Summary

Novavax beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Novavax compare to Ocugen?

Novavax (NASDAQ:NVAX) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 1.0% of Novavax shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.35	$440.30M	-$0.58	N/A
Ocugen	$4.41M	102.86	-$67.85M	-$0.24	N/A

Novavax presently has a consensus price target of $12.13, indicating a potential upside of 31.65%. Ocugen has a consensus price target of $9.75, indicating a potential upside of 627.61%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Novavax has a net margin of -14.73% compared to Ocugen's net margin of -1,192.18%. Novavax's return on equity of -14.82% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

Novavax has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

In the previous week, Novavax had 7 more articles in the media than Ocugen. MarketBeat recorded 7 mentions for Novavax and 0 mentions for Ocugen. Novavax's average media sentiment score of 0.03 beat Ocugen's score of 0.00 indicating that Novavax is being referred to more favorably in the media.

Company	Overall Sentiment
Novavax	Neutral
Ocugen	Neutral

Summary

Novavax beats Ocugen on 10 of the 16 factors compared between the two stocks.

How does Novavax compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are related companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 1.0% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Astrazeneca had 4 more articles in the media than Novavax. MarketBeat recorded 11 mentions for Astrazeneca and 7 mentions for Novavax. Astrazeneca's average media sentiment score of 0.42 beat Novavax's score of 0.03 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	5 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Novavax has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market.

Astrazeneca currently has a consensus price target of $205.33, indicating a potential upside of 9.66%. Novavax has a consensus price target of $12.13, indicating a potential upside of 31.65%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novavax	-14.73%	-14.82%	1.23%

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.94	$10.23B	$6.66	28.11
Novavax	$1.12B	1.35	$440.30M	-$0.58	N/A

Summary

Astrazeneca beats Novavax on 12 of the 16 factors compared between the two stocks.

How does Novavax compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Novavax	-14.73%	-14.82%	1.23%

Johnson & Johnson has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Novavax has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.00	$26.80B	$8.65	27.13
Novavax	$1.12B	1.35	$440.30M	-$0.58	N/A

In the previous week, Johnson & Johnson had 78 more articles in the media than Novavax. MarketBeat recorded 85 mentions for Johnson & Johnson and 7 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.22 beat Novavax's score of 0.03 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	67 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Johnson & Johnson presently has a consensus target price of $253.04, suggesting a potential upside of 7.83%. Novavax has a consensus target price of $12.13, suggesting a potential upside of 31.65%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Summary

Johnson & Johnson beats Novavax on 13 of the 16 factors compared between the two stocks.

How does Novavax compare to Pfizer?

Pfizer (NYSE:PFE) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Pfizer presently has a consensus target price of $28.61, suggesting a potential upside of 10.39%. Novavax has a consensus target price of $12.13, suggesting a potential upside of 31.65%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.19
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Pfizer has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Novavax has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Novavax	-14.73%	-14.82%	1.23%

68.4% of Pfizer shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 1.0% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Pfizer had 62 more articles in the media than Novavax. MarketBeat recorded 69 mentions for Pfizer and 7 mentions for Novavax. Pfizer's average media sentiment score of 0.89 beat Novavax's score of 0.03 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	44 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	5 Very Negative mention(s)	Positive
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.36	$7.77B	$1.31	19.79
Novavax	$1.12B	1.35	$440.30M	-$0.58	N/A

Summary

Pfizer beats Novavax on 13 of the 16 factors compared between the two stocks.

Get Novavax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVAX vs. The Competition

Export

Metric	Novavax	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.51B	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-15.88	18.74	21.22	25.65
Price / Sales	1.35	323.98	553.92	86.28
Price / Cash	2.62	125.17	43.49	56.67
Price / Book	-10.47	7.09	10.37	7.14
Net Income	$440.30M	$24.45M	$3.57B	$335.98M
7 Day Performance	3.14%	5.45%	6.01%	3.56%
1 Month Performance	12.04%	2.43%	3.52%	2.54%
1 Year Performance	27.03%	62.98%	34.13%	35.05%

Novavax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVAX Novavax	1.777 of 5 stars	$9.21 flat	$12.13 +31.7%	+27.0%	$1.51B	$1.12B	N/A	1,990	Analyst Downgrade Analyst Revision Gap Down
MRNA Moderna	1.2866 of 5 stars	$48.11 -1.9%	$35.73 -25.7%	+78.5%	$19.09B	$1.94B	N/A	4,700	Insider Trade
OCGN Ocugen	1.586 of 5 stars	$1.34 -3.6%	$9.75 +627.6%	+44.0%	$453.62M	$4.41M	N/A	80
AZN Astrazeneca	3.7371 of 5 stars	$183.97 +1.3%	$205.33 +11.6%	N/A	$285.32B	$60.44B	27.62	96,100
JNJ Johnson & Johnson	4.3407 of 5 stars	$228.80 +0.9%	$253.04 +10.6%	+53.3%	$550.76B	$94.19B	26.45	138,200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVAX) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novavax (NVAX) Competitors